BioCentury | Jun 19, 2020
Product Development

BEATing COVID-19 from home

As knowledge regarding the natural history of COVID-19 continues to evolve, biopharmas are looking to real-world data generated from the BEAT19 initiative to inform clinical trial design for COVID-19 therapies. Behavior, Environment and Treatments for...
BioCentury | Apr 25, 2020
Product Development

Mesoblast’s stem cells boost survival to 83% in COVID-19 patients with ARDS; Arch also taking aim at respiratory distress

Two weeks after Mesoblast announced a randomized controlled trial of its stem cell therapy to treat COVID-19 patients with acute respiratory distress syndrome, it has revealed compassionate use data backing the study. Also targeting ARDS...
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

...managed with immunosuppressants or steroids to dampen autoantibody production; plasmapheresis to remove the autoantibodies; or AChE...
...social well-being. Sources: FDA label, company press releases, JAMA Neurology, Neurology, clinicaltrials.gov Targets AChE - acetylcholinesterase...
BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

Alexion’s proposed takeout of Achillion would complete a 21-year journey that saw the latter evolve from an antiviral play into a complement pathway company. For Alexion, it represents the next step in its quest to...
BioCentury | Jul 23, 2019
Clinical News

July 23 Clinical Quick Takes: Achillion plans U.S. IND; plus Chiasma, Myovant, Marinus and Merck

Achillion plans U.S. IND after latest readout for ACH-5228 Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) rose $1.19 (50%) to $3.57 since announcing early Monday that multiple ascending doses of its CFD inhibitor ACH-5228 led to 95% complement...
BioCentury | May 17, 2019
Clinical News

May 17 Clinical Quick Takes: Achillion Phase III plans for PNH combo; plus NCI, MorphoSys

Achillion to start Phase III of PNH combo in 1H20 Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will start in 1H20 a Phase III trial evaluating oral CFD inhibitor ACH-4471 in combination with C5 inhibitors to...
BioCentury | Mar 23, 2019
Product Development

Baby steps beyond beta amyloid

...already approved to treat Alzheimer’s disease, such as transdermal or extended-release NMDA receptor antagonists or acetylcholinesterase (AChE)...
BioCentury | Dec 21, 2018
Clinical News

Achillion discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound. The decision is a delay for Achillion as it...
BioCentury | Dec 19, 2018
Clinical News

Achillion down after discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) lost $0.45 (19%) to $1.95 on Tuesday after it said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound....
Items per page:
1 - 10 of 621